Astellas Pharma Europe Ltd (APEL) has appointed Dr Christopher Thomson as Executive Director of its new European Oncology Unit.
Dr Thomson joined APEL in 2008 and takes the new position after working as the Director of Business Development.
Ken Jones, President and CEO of APEL, said: “He has been involved in key negotiations with our partners and we are committed to developing a portfolio of treatments urgently to fulfil the unmet medical needs that exist in oncology.”
APEL’s move into oncology will be complemented by the expansion of its transplantation, urology, anti-infectives, dermatology and pain management franchises.
“This is a very exciting opportunity to spearhead APEL’s move into oncology, an area in which I believe we have the expertise, resources and relationships to make a real contribution to creating a brighter future for patients,” Dr Thomson said.
Astellas Pharma Europe Ltd. is a European subsidiary of Astellas Pharma Inc. which is based in Tokyo and provides pharmaceuticals around the world, with locations in Europe, the Middle East and Africa.